18496750

Source:http://linkedlifedata.com/resource/pubmed/id/18496750

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0036043, umls-concept:C0205179, umls-concept:C0278488, umls-concept:C1135135, umls-concept:C1517927
pubmed:issue	1
pubmed:dateCreated	2009-4-23
pubmed:abstractText	To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines, taxanes, and capecitabine (n = 47). Cohort 2: progression after >1 chemotherapy for advanced-stage disease (n = 22). Primary endpoint was response rate (World Health Organization criteria). Secondary endpoints were safety, time to progression, and survival.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8111104
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anthracyclines, http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor, http://linkedlifedata.com/resource/pubmed/chemical/Taxoids, http://linkedlifedata.com/resource/pubmed/chemical/capecitabine, http://linkedlifedata.com/resource/pubmed/chemical/erlotinib
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	1573-7217
pubmed:author	pubmed-author:CobleighMelody AMA, pubmed-author:DicklerMaura NMN, pubmed-author:KleinPamela MPM, pubmed-author:MillerKathy DKD, pubmed-author:WinerEric PEP
pubmed:issnType	Electronic
pubmed:volume	115
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	115-21
pubmed:dateRevised	2009-11-19
pubmed:meshHeading	pubmed-meshheading:18496750-Adult, pubmed-meshheading:18496750-Aged, pubmed-meshheading:18496750-Aged, 80 and over, pubmed-meshheading:18496750-Anthracyclines, pubmed-meshheading:18496750-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:18496750-Breast Neoplasms, pubmed-meshheading:18496750-Cohort Studies, pubmed-meshheading:18496750-Deoxycytidine, pubmed-meshheading:18496750-Disease Progression, pubmed-meshheading:18496750-Female, pubmed-meshheading:18496750-Fluorouracil, pubmed-meshheading:18496750-Humans, pubmed-meshheading:18496750-Middle Aged, pubmed-meshheading:18496750-Neoplasm Metastasis, pubmed-meshheading:18496750-Protein Kinase Inhibitors, pubmed-meshheading:18496750-Quinazolines, pubmed-meshheading:18496750-Receptor, Epidermal Growth Factor, pubmed-meshheading:18496750-Taxoids
pubmed:year	2009
pubmed:articleTitle	Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
pubmed:affiliation	Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. dicklerm@mskcc.org
pubmed:publicationType	Journal Article, Multicenter Study, Clinical Trial, Phase II